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What is known on this topic 
 
 PCDT did not prevent the post thrombotic syndrome in patients with acute deep vein 
thrombosis (DVT) in the ATTRACT trial but improved a number of short- and long-term 
secondary outcomes. 
 It is uncertain if the benefit of PCDT in ATTRACT occurred in patients with femoral-




What this paper adds 
 
 Detailed analysis of a broad range of short- and long-term outcomes in 300 patients with 
femoral-popliteal DVT. 
 PCDT did not improve any short- or long-term outcomes, but increased bleeding. 




Background and Objectives: The ATTRACT trial reported that pharmacomechanical catheter-
directed thrombolysis (PCDT) did not reduce postthrombotic syndrome (PTS), but reduced 
moderate-to-severe PTS and the severity of PTS symptoms. In this analysis, we examine the 
effect of PCDT in patients with femoral-popliteal DVT (without involvement of more proximal 
veins). 
Patients/Methods: Within the ATTRACT trial, 300 patients had deep vein thrombosis (DVT) 
involving the femoral vein without involvement of the common femoral or iliac veins and were 
randomized to receive PCDT with anticoagulation or anticoagulation alone (No PCDT). Patients 
were followed for 24 months.     
Results: From 6 to 24 months, between the PCDT vs. No PCDT arms, there was: no difference in 
any PTS (Villalta scale ≥5: Risk Ratio [RR]=0.97; 95% confidence interval [CI], 0.75 to 1.24); 
moderate-or-severe PTS (Villalta scale ≥10: RR=0.93; 95% CI, 0.57 to 1.52; severity of PTS 
scores; or general or disease-specific quality of life (p >0.5 for all comparisons). From baseline 
to both 10 days and 30 days, there was no difference in improvement of leg pain or swelling  
between treatment arms. From baseline to 10 days, major bleeding occurred in three vs. none 
(p=0.06) and any bleeding occurred in eight vs. two (p=0.032) PCDT vs. No PCDT patients. 
Over 24 months, recurrent venous thromboembolism occurred in 16 PCDT and 12 No PCDT 
patients (p=0.24). 
Conclusion: In patients with femoral-popliteal DVT, PCDT did not improve short- or long-term 
efficacy outcomes, but it increased bleeding. Therefore, PCDT should not be used as initial 




Pharmacomechanical catheter directed thrombolysis (PCDT), which refers to mechanical 
thrombus disruption in combination with thrombolytic therapy, rapidly removes thrombus and 
has the potential to improve both short- and long-term outcomes in patients with acute deep vein 
thrombosis (DVT). We recently reported the findings of the Acute Venous Thrombosis: 
Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) Trial which 
compared PCDT with No PCDT (i.e. anticoagulation alone) in patients with acute DVT that 
involved the femoral or more proximal veins.(1;2) PCDT did not reduce the primary outcome of  
any post thrombotic syndrome (PTS) but reduced the secondary outcomes of moderate-or-severe 
PTS and the severity of PTS symptoms and signs. Acutely, PCDT also reduced leg pain and 
swelling but increased bleeding.  
Among ATTRACT patients, there were important differences in the anatomic extent of 
DVT present at randomization, and these differences may have influenced the benefits and risks 
of PCDT. For example, patients with more extensive proximal DVT have a higher risk of 
recurrence, are more likely to develop PTS, and have more severe PTS than patients with less 
extensive DVT.(3;4) To minimize imbalances in the extent of DVT that was present in the PCDT 
and No PCDT treatment arms, randomization in ATTRACT was stratified according to the 
extent of DVT at diagnosis. In the current analyses, which were pre-planned, we explore the 
benefits and risks of PCDT in the subgroup of ATTRACT patients who had femoral-popliteal 





Study patients and clinical management 
The design and main results of ATTRACT have previously been described.(1;2) In brief, 
patients 16 to 75 years old with symptomatic DVT that involved the femoral, common femoral, 
or iliac veins (with or without other involved veins) were enrolled provided they did not have 
symptoms for more than 14 days, high bleeding risk, active cancer, established PTS, or 
ipsilateral DVT in the previous 2 years. Patients were enrolled in community and university-
based clinical centers in the US. The study was approved by the research ethics boards of 
participating institutions and all patients provided informed consent.  
Patients' baseline characteristics, including whether they had iliofemoral or femoral-
popliteal DVT, were assessed before randomization. To be included in the femoral-popliteal 
randomization stratum and, therefore, eligible for inclusion in the current analysis, patients were 
to have thrombus in the femoral (with or without involvement of the popliteal vein) but not the 
common femoral vein or the iliac vein. 
Patients were randomized in a 1:1 ratio to PCDT or to No PCDT. In addition to 
stratification as "femoral-popliteal" and "iliofemoral" DVT, patients were also stratified by 
clinical center. Patients in both the PCDT and No PCDT arms received anticoagulant therapy 
and elastic compression stockings. PCDT was done using one of three methods. If the popliteal 
vein was occluded, patients initially received recombinant tissue plasminogen activator (rt-PA) 
infusion through a multi-sidehole catheter for ≤30 hours ("infusion-first" method). If the 
popliteal vein was patent, patients initially received rapid delivery of rt-PA through either the 
AngioJet Rheolytic Thrombectomy System (Boston Scientific, Marlborough, MA) or the Trellis 
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Peripheral Infusion System (Covidien, Inc., Mansfield, MA). After initial delivery of rt-PA, 
physicians could use balloon maceration, catheter aspiration, AngioJet or Trellis thrombectomy, 
percutaneous transluminal balloon venoplasty, stent placement (iliac or common femoral vein), 
continued rt-PA infusion through a multi-sidehole catheter, or a combination of procedures, to 
clear residual thrombus and treat obstructive lesions. Stenting of the iliac or common femoral 
vein was encouraged if there were obstructive lesions (e.g. extrinsic compression such as May-
Thurner Syndrome) with ≥50% diameter narrowing, robust collateral filling, or a mean 
translesional pressure gradient >2 mmHg . Treatment was discontinued when there was at least 
90% thrombus removal with restoration of flow, or a serious complication. The maximum 
allowable total dose of rt-PA for initial and follow-up procedures was 35 mg. 
 
Follow-up and outcomes 
Study outcomes were assessed at 10 and 30 days, and at 6, 12, 18, and 24 months post-
randomization. The primary efficacy outcome was the presence of PTS, defined as a Villalta 
scale score ≥5 or an ulcer, in the leg with the index DVT, between the 6-month and the 24-month 
follow-up visits.(5;6) The Villalta scale rates the severity, from 0 to 3, of five patient-reported 
symptoms (pain, cramps, heaviness, pruritus, paresthesia) and six clinician-observed signs 
(edema, skin induration, hyperpigmentation, venous ectasia, redness, pain during calf 
compression). Points for symptoms and signs are summed into a total score (range 0-33), and 
patients can be categorized as having no PTS (score 0-4), mild PTS (score 5-9), moderate PTS 
(score 10-14) or severe PTS (score >14, or presence of ulcer). Patients were also counted as 
having PTS if they had an unplanned endovascular procedure to treat severe venous symptoms 
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more than 6 months after randomization, unless there was a Villalta <5 in the preceding 4 weeks. 
Major non-PTS treatment failures were also assessed.(2) 
Using the Villalta scale, the presence of moderate-or-severe PTS (Villalta scale score 
≥10, or an ulcer), or severe PTS (Villalta scale score ≥15, or an ulcer) were assessed as 
secondary outcomes. Using the Venous Clinical Severity Score (VCSS; ranges from 0 to 27, 
with higher scores indicating more severe PTS), the presence of PTS (VCSS ≥4) or severe PTS 
(VCSS ≥8) were also assessed.(7) The proportion of patients with a Villalta scale score ≥5 and 
≥10, and a VCSS ≥4 and ≥8 at each visit was recorded. The severity of PTS was evaluated at 6, 
12, 18 and 24 months using the Villalta scale and the VCSS as continuous measurements. Leg 
pain and leg swelling were assessed at baseline, 10 days, and 30 days, using a 7-point Likert pain 
scale and by measuring calf circumference.  
In the PCDT arm, thrombus removal was quantified using the proximal vein components 
of the Marder score (0 to 24, with 24 representing complete thrombosis) by independent central 
readers who scored venograms done before and after the procedure.(8)  
Safety outcomes included bleeding, recurrent venous thromboembolism, and deaths, 
which were reported throughout follow-up and summarized through 10 days. 
General health-related quality of life was assessed with the SF-36 Health Status Survey 
and venous disease-specific quality of life was assessed with the Venous Insufficiency 
Epidemiological and Economic Study (VEINES-QOL) measure.(9;10)  Detailed definitions of 
trial outcomes have previously been reported.(1;2) Both the clinical personnel who administered 




Sample size for the whole ATTRACT study was 692 patients based on the following 
assumptions: 30% of control patients would develop PTS between 6 and 24 months; PCDT 
would reduce PTS by at least 33%; 10% loss to follow-up; need to have 80% power to detect the 
hypothesized treatment effect; acceptance of a two-side α error of 0.05. We did not prespecify 
the proportion of enrolled patients who were expected to have femoral-popliteal DVT, nor did 
we require that a minimum number of femoral-popliteal DVT patients be included. A sample 
size of 300, corresponding to the number of patients in the current analysis, provides 
approximately 80% power to detect a 47% PTS reduction assuming a control proportion of 30%, 
and an effect size (i.e. mean difference divided by the standard deviation) of at least 0.32, 
assuming a two-sided α=0.05 with each type of analysis. 
Statistical Analysis 
Two types of analyses were performed: a modified intention-to-treat analysis (primary 
analysis) that included all randomized patients except those who did not have DVT at 
enrollment; and a per-protocol analysis (secondary analyses) that excluded patients who, within 
7 days post-randomization, were randomized to PCDT but did not receive it, or who were 
randomized to control but had skin puncture for PCDT thrombolysis or any thrombolytic 
therapy. 
Cumulative proportions were compared using the Cochran-Mantel-Haenszel test adjusted 
for clinical center. Treatment effects are summarized using stratum-adjusted risk ratios (RR) 
with their corresponding 95% confidence intervals (CI).  
The mean Villalta and VCSS assessments at each visit were estimated using piece-wise 
linear regression growth curve models adjusting for clinical center and pre-specified baseline 
10 
 
covariates (age, sex, body mass index [BMI], race). Changes from baseline to 10 and 30 days for 
leg pain scores and calf circumferences, were compared between the two arms using linear 
regression, adjusted for clinical center.  
Results 
Baseline Characteristics 
Of the 692 patients in ATTRACT, 300 (43%) had femoral-popliteal DVT of whom 140 
were randomized to PCDT and 160 were randomized to No PCDT (Fig. 1). Median age was 53 
years, 73% were male, the index DVT was in the left leg in 59% and symptoms were present for 
a median of 7 days. Baseline characteristics were well balanced between the two treatment arms 
(Table 1). 
Protocol and Treatment Adherence 
Within 7 days after randomization, 1 patient assigned to No PCDT had PCDT, and 5 
patients assigned to PCDT did not have the procedure (Fig. 1). These patients were excluded 
from the per-protocol analysis. PCDT was performed a median of one day post-randomization. 
Initial anticoagulant therapy, which was usually low molecular weight heparin or unfractionated 
heparin, was similar in the PCDT and No PCDT arms (Table 2). 
In PCDT patients, initial rt-PA delivery was with the "infusion-first" method in 66% 
(median total rt-PA dose of 22 mg), the AngioJet method in 21% (median total rt-PA dose of 21 
mg), and the Trellis method in 9% (median total rt-PA dose of 14 mg); 5% did not recieve rt-PA 
(Table 2). After initial rt-PA delivery, additional endovascular methods were used in 85% of 
patients (summarized in Table 2). Mean percent thrombus removal, as assessed by pre- and post-
PCDT venography, was 79% (95% CI, 74% to 83%). The mean pre- and post-lysis Marder 
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scores were 10.2 and 2.1 respectively (mean change was -8.1; 95% CI, -7.2 to -8.9; p<0.001). 
The mean duration of anticoagulation before first permanent cessation during follow-up, use of 
antiplatelet therapy, and use of compression stockings were similar in the PCDT and No PCDT 
arms (Table 2).  
Primary Efficacy Outcome 
PTS, as assessed by a Villalta scale score ≥5 or ulceration, developed in 61 (44%) 
patients assigned to PCDT and 71 (44%) patients assigned to No PCDT over 24 months 
(RR=0.97; 95% CI, 0.75 to 1.24; p=0.79; Table 3). The findings were similar in a per-protocol 
analysis (59 of 135 with PCDT vs. 70 of 159 with No PCDT, RR=0.97; 95% CI, 0.75 to 1.25; 
Supplementary Table S1). Results were similar in pre-specified subgroups, except for a 
suggestion that the treatment effect of PCDT may have been more favorable in patients with a 
major reversible risk factor when the DVT occurred compared to those without such a risk factor 
(p interaction=0.04; Fig. 2). 
Secondary Efficacy Outcomes 
 Moderate-or-severe PTS, as assessed by a Villalta scale score ≥10 or ulceration, 
developed in 24 (17%) patients assigned to PCDT and 29 (18%) patients assigned to No PCDT 
(RR=0.93; 95% CI, 0.57 to 1.52; p=0.77) (Table 3). The findings were similar in a per-protocol 
analysis (Supplementary Table S1). Results were similar in pre-specified subgroups except for a 
suggestion that the treatment effect of PCDT may have been more favorable in patients with 
higher baseline Villalta scores (p interaction=0.03; Fig. 3).  
 Severe PTS, as assessed by a Villalta scale score ≥15 or ulceration, developed in 10 (7%) 
patients assigned to PCDT and 13 (8%) patients assigned to No PCDT (RR=0.84; 95% CI, 0.37 
to 1.87; p=0.66; Table 3). Ulceration developed in 3 (2.1%) patients assigned to PCDT and 5 
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(3.1%) patients assigned to No PCDT (Table 3). The proportion of patients who had PTS, or 
moderate-or-severe PTS, as assessed by the Villalta scale, at each 6, 12, 18 and 24-month visit 
are shown in Table 3; these proportions did not differ between the PCDT vs. No PCDT arms at 
any of the follow-up visits. The above findings were similar in a per-protocol analysis 
(Supplementary Table S1). 
 PTS, as assessed by a VCSS ≥4, developed in 43 (31%) patients assigned to PCDT and 
50 (31%) patients assigned to No PCDT (RR=0.99; 95% CI, 0.72 to 1.38; p=0.97; Table 3). 
Severe PTS, as assessed by a VCSS ≥8, developed in 9 (6%) patients assigned to PCDT and 14 
(9%) patients assigned to No PCDT (RR=0.76; 95% CI, 0.35 to 1.65; p=0.49; Table 3). The 
findings for these two outcomes were similar in a per-protocol analysis (Supplementary Table 
S1). 
 There was no difference in PTS severity, as assessed by mean Villalta score and mean 
VCSS, between the PCDT and No PCDT arm from 6 to 24 months in the modified intention-to-
treat (Table 4) nor the per-protocol analyses (Supplementary Table S2). 
 Mean change in leg pain from baseline for PCDT vs. No PCDT was -1.44 vs. -1.35 Likert 
points at 10 days (p=0.68), and -1.93 vs. -1.88 Likert points at 30 days (p=0.85). Mean change in 
leg circumference from baseline for PCDT vs. No PCDT was 0.45 cm vs. 0.37 cm at 10 days 
(p=0.81), and 0.08 cm vs. -0.41 cm at 30 days (p=0.14). The findings for these outcomes were 
similar in the per-protocol analyses (Supplementary Table S2). 
 Mean change in general quality of life and in disease-specific quality of life from baseline 
to 30 days and from baseline to 24 months did not differ between the PCDT vs. No PCDT arms 





Within 10 days, in PCDT vs. No PCDT patients, major bleeding occurred in 3 (2.1%) vs. 
no patients (p=0.063; none were fatal or intracranial), and any bleeding occurred in 8 (5.7%) vs. 
2 (1.3%) patients (p=0.032; Table 3). Recurrent venous thromboembolism within 24 months 
occurred in 16 (11%) PCDT vs. 12 (8%) No PCDT patients (p=0.24) (none were fatal). Three 
deaths were observed during the study: one in the PCDT arm and 2 in the No PCDT arm. None 
occurred within 10 days post-randomization (Table 3). 
 
Discussion  
This analysis found that PCDT did not improve any prespecified short-term or long-term 
efficacy outcomes but increased bleeding in ATTRACT trial patients who had femoral-popliteal 
DVT. Within the femoral-popliteal subgroup of ATTRACT patients, there was a suggestion that 
PCDT may have reduced "any PTS" more in patients whose DVT was provoked by a major risk 
factor (e.g. recent surgery), and may have reduced moderate-or-severe PTS more in patients who 
had higher Villalta scores at baseline. However, as there were many subgroup comparisons and 
as the tests of interaction were not strongly statistically significant, it is likely that these two 
findings occurred by chance and that the treatment responses did not truly differ between these 
subgroups.(11;12) During follow-up, the prevalence of PTS of 44% in both treatment groups 
indicates that PTS remains a substantial problem in patients who have femoral-popliteal DVT. 
Unlike in the overall study, PCDT did not appear to reduce early symptoms of leg pain or 
leg swelling or the occurrence of moderate-or-severe PTS in the femoral-popliteal DVT 
subgroup. This suggests that, as we have reported elsewhere, improvements in these outcomes 
with PCDT was confined to the iliofemoral DVT subgroup.(13)  
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The CAVENT (Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein 
Thrombosis) trial, which evaluated 209 patients, reported that catheter-directed thrombolysis 
reduced the risk of PTS at 2 and 5 years but did not report findings separately for patients with 
femoral-popliteal (required involvement "above mid-thigh level") and iliofemoral DVT.(14;15) 
Our analysis has several limitations. As only 43% of ATTRACT trial patients had femoral-
popliteal DVT, power to detect difference in outcomes with PCDT vs. No PCDT in the femoral-
popliteal subgroup is substantially less than in the overall trial. Furthermore, in the absence of a 
statistically significant test of interaction to support a difference in the PCDT treatment effect 
between the femoral-popliteal and iliofemoral subgroups, the treatment effect estimate from the 
overall trial may be the most reliable estimate of the treatment effect in each of the femoral-
popliteal and the iliofemoral subgroups.(11;12) However, as the risk of developing PTS is 
influenced by the extent of DVT, it is important to understand outcomes in the ATTRACT 
patients whose proximal DVT was confined to the femoral vein.(4) Another limitation is that 
more patients were lost to follow-up in the No PCDT arm (28% versus 16%) which has 
the potential to reduce the apparent efficacy of PCDT in our analysis. An additional 
sensitivity analysis for the primary outcome of any PTS, after using multiple imputation 
to replace missing data, found a risk ratio of 0.84 (95%CI, 0.67 to 1.04) for PCDT 
compared with control. 
A strength of these analyses is that they were prespecified, and that the femoral-popliteal 
and iliofemoral subgroups were stratification factors in the randomization of patients to PCDT 
and No PCDT. An additional limitation is that differences in the occurrence of PTS between the 
treatment groups might emerge with longer than two years of follow-up. 
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In conclusion, whereas the overall findings of ATTRACT found suggested that PCDT 
reduced moderate-or-severe PTS, reduced the severity of PTS symptoms, and improved recovery 
of leg pain and swelling, the current analysis does not support such benefits in patients with 
femoral-popliteal DVT. As PCDT is associated with bleeding, early PCDT does not appear to be 
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Table 1: Baseline Characteristics by Treatment Group 
Baseline Characteristic 
PCDT Arm Control Arm Total 
n = 140 n = 160 N = 300 
Age, years: median (IQR)    53 (43, 60) 54 (44, 63) 53 (43, 62) 
Male: n (%)  98 (70)  120 (75)  218 (73) 
Race: n (%)    
White  107 (76)  128 (80)  235 (78) 
Black/African-American  28 (20)  27 (17)  55 (18) 
Other  5 (4)  5 (3)  10 (3) 
Body mass index, kg/m2: median (IQR) 30 (27, 35) 30 (26, 34) 30 (27, 35) 
Symptom severity (Villaltaa) class: n (%)b    
None or minimal (score 0-4)  33 (24)  38 (24)  71 (24) 
Mild (score 5-9)  50 (36)  59 (37)  109 (36) 
Moderate (score 10-14)  38 (27)  38 (24)  76 (25) 
Severe (score ≥ 15)  19 (14)  24 (15)  43 (14) 
Leg with index DVT, Left: n (%)  83 (59)  93 (58)  176 (59) 
Previous DVT or PE: n (%)  35 (25)  42 (26)  77 (26) 
Previous ipsilateral DVT: n (%)  2 (1)  4 (3)  6 (2) 
DVT risk factors: n (%)c    
Major surgery  8 (6)  13 (8)  21 (7) 
Hospitalization  9 (6)  9 (6)  18 (6) 
Plaster cast immobilization  1 (1)  6 (4)  7 (2) 
Outpatient: n (%)  112 (80)  144 (90)  256 (85) 
Days from start of DVT symptoms to rand: median (IQR) 6 (4, 11) 7 (4, 10)  7 (4, 10) 
eGFR, mL/min: median (IQR) 89 (73, 101) 83 (71, 99) 86 (72, 100) 
Leg pain severity: n (%)    
0-2  26 (19)  38 (24)  64 (21) 
3-4  60 (43)  55 (34)  115 (38) 
5-7  53 (38)  65 (41)  118 (39) 
Unknown  1 (1)  2 (1)  3 (1) 
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Between-leg circumference differenced, cm: median 
(IQR) 
 2 (1, 3)  2 (1, 3) 2 (1, 3) 
Pre-randomization ACe therapy: n (%)c  134 (96)  147 (92)  281 (94) 
LMWH   79 (59)  95 (65)  174 (62) 
UFH  38 (28)  39 (27)  77 (27) 
Rivaroxaban  9 (7)  4 (3)  13 (5) 
Warfarin  65 (49)  81 (55)  146 (52) 
Other  7 (5)  9 (6)  16 (6) 
IQR, inter-quartile range; DVT, deep vein thrombosis; PE, pulmonary embolism; rand, randomization; 
eGFR, estimated glomerular filtration rate; LMWH, low molecular weight heparin; UFH, unfractionated 
heparin  
 
a  Villalta Scale: 5 patient-reported signs (cramps, itching, pins & needles, leg heaviness, pain) and 6 
blinded clinician-reported symptoms (pretibial edema, skin induration, hyperpigmentation, venous 
ectasia, redness, pain during calf compression) scored on a 4-point scale (0=none/minimal, 1=mild, 
2=moderate, 3=severe) and summed into a total score, or the presence of an ulcer (score=15), for 
each leg 
b  One patient in the control arm were not assessed 
c  Subjects may fit into more than one category 
d  Circumference of leg with index DVT minus circumference of the other leg 





Table 2: Study Treatments Post Randomization 
Treatment over Time 
PCDT Arm 
n = 140 
Control Arm 
n = 160 
Initial AC a therapy: n (%)b n = 140 n = 160 
UFH  45 (32)  27 (17) 
LMWH  82 (59)  95 (59) 
Other   18 (13)  41 (26) 
At 30 days: n (%)b n = 138 n = 149 
Any AC therapy  138 (100)  149 (100) 
Antiplatelet therapy  17 (12)  17 (11) 
Compression stockings used ≥ 3 days per week  110 (80)  116 (78) 
At 6 months: n (%)b n = 121 n = 136 
Any AC therapy  91 (75)  120 (88) 
Antiplatelet therapy  26 (21)  15 (11) 
Compression stockings used ≥ 3 days per week  81 (67)  89 (65) 
At 24 months: n (%)b n = 110 n = 106 
Any AC therapy  55 (50)  49 (46) 
Antiplatelet therapy  28 (25)  23 (22) 
Compression stockings used ≥ 3 days per week  61 (55)  56 (53) 
Duration of AC therapy: n (%) n = 140 n = 160 
Never started  0  0 
Not stopped during study period  71 (51)  90 (56) 
Stopped during study period:   69 (49)  70 (44) 
Days to stopping: median (IQR)  215 (184, 369)  223 (190, 300) 
 
PCDT Procedure Details (PCDT Arm only) 
Initial rt-PA delivery method:   
Infusion-First: n (%)  92 (66)  
rt-PA total dose, mg: median (IQR) 22 (17, 25)  
rt-PA duration, hours: % below 4h, mean (SD) c 0%, 21 (5.4)  
AngioJet: n (%)  29 (21)  
rt-PA total dose, mg: median (IQR) 21 (10, 28)  
rt-PA duration, hours: % below 4h, mean (SD‡ 41%, 20 (5.0)  
Trellis: n (%)  12 (9)  
rt-PA total dose, mg: median (IQR) 14 (11, 23)  




Other:d n (%)  7 (5)  
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Additional endovascular methods used: n (%)   
None   21 (15)  
1 or more  119 (85)  
Type of additional method: n (%)b   
Balloon venoplasty  57 (48)  
Balloon maceration  78 (66)  
Rheolytic thrombectomy (AngioJet)  76 (64)  
Stent placement  12 (10)e  
Large-bore catheter aspiration  19 (16)  
Isolated thrombolysis (Trellis)  3 (3)  
Veins that were accessed: n (%)b  137 (98)  
Ipsilateral popliteal vein  102 (74)  
Ipsilateral tibial vein  39 (28)  
Ipsilateral common femoral vein  3 (2)  
Internal jugular vein  4 (3)  
Other vein  9 (7)  
Marder scores: median (IQR)   
Pre lysis  10 (7, 13)  
Post lysis   1  (0,   3)  
 
IQR, Inter-quartile range; rt-PA, recombinant tissue plasminogen activator; SD, standard 
deviation 
 
a Anticoagulation (AC) therapy given post randomization 
b Subjects may fit into more than one category 
c Distributions are bimodal with spikes below 4 hours (means and SDs are for post 4-hour 
data)  
d 4 PCDT procedures where there was no acute thrombus on venogram and 3 not attempted 
e  Stents were placed in the iliac vein in 11 patients (reasons: stenosis in 9, extrinsic 
compression in 4, not specified in 1) and in the femoral vein in 1 patient (reason: stenosis 





Table 3: Binary Study Outcomes by Treatment Group (Intention To Treat) 
Outcome 
PCDT Arm 
n = 140 
Control Arm 
n = 160 
Risk Ratio P 
Value 
Events (%) Events (%) Estimate 95% CI 
PTS:a        
Ulcer (any assessment) 3 (2.1%) 5 (3.1%)    
Villalta ≥ 5 (without ulcer) 58 (41%) 66 (41%)    
Late endovascular procedure only 0 (0%) 0 (0%)    
Total 61 (44%) 71 (44%) 0.97b 0.75, 1.24 0.79 
PTS: VCSS ≥ 4a 43 (31%) 50 (31%) 0.99b 0.72, 1.38 0.97 
PTS incidence proportion:c        
At 6 months 28/122 (23%) 45/136 (33%) 0.69 0.46, 1.04  
At 12 months 34/117 (29%) 39/121 (32%) 0.90 0.61, 1.32  
At 18 months 39/106 (37%) 29/99 (29%) 1.26 0.85, 1.86  
At 24 months 31/113 (27%) 34/107 (32%) 0.86 0.57, 1.30  
Moderate-severe PTS (Villalta ≥ 10)d 24 (17%) 29 (18%) 0.93  0.57, 1.52 0.77 
Moderate-severe PTS incidence 
proportion:e 
       
At 6 months 10/122 (8%) 14/136 (10%) 0.80 0.37, 1.73  
At 12 months 13/117 (11%) 9/121 (7%) 1.49 0.66, 3.36  
At 18 months 13/106 (12%) 11/99 (11%) 1.10 0.52, 2.35  
At 24 months 12/113 (11%) 15/107 (14%) 0.76 0.37, 1.54  
Severe PTS: Villalta ≥ 15f 10 (7.1%) 13 (8.1%) 0.84  0.37, 1.87 0.66 
Severe PTS: VCSS ≥ 8f 9 (6.4%) 14 (8.8%) 0.76b 0.35, 1.65 0.49 
Major non-PTS treatment failure 0 (0%) 2 (1.3%) 0.23 0.01, 4.72 0.19 
Any treatment failureg 61 (44%) 73 (46%) 0.94b 0.73, 1.21 0.65 
Major bleeding in first 10 days 3 (2.1%) 0 (0%) 7.99 0.42, 153 0.063 
Any bleeding in first 10 days 8 (5.7%) 2 (1.3%) 4.57 0.99, 21.2 0.032 
VTE:        
First 30 days 4 (2.9%) 2 (1.3%) 2.29 0.43, 12.3 0.32 
Total over 24 months 16 (11%) 12 (8%) 1.52 0.75, 3.11 0.24 
Death  1 (0.7%) 2 (1.3%) 0.57 0.05, 6.23 0.64 
PTS, post-thrombotic syndrome; CI, confidence interval; VTE, venous thromboembolism 
a Cumulative proportion of patients who developed PTS (ulcer, Villalta ≥ 5 or LEP) at any time between 6 and 
24 months inclusive;  
b Cochran-Mantel-Haenszel (CMH) test adjusted for center;  
c At each visit, the proportion of patients with any PTS according to the Villalta scale among those who had an 
assessment performed (denominator);  
d  Cumulative proportion with moderate or severe PTS (pre-specified analysis);  
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e  At each visit, the proportion of patients with any moderate or severe PTS according to the Villalta scale 
among those who had an assessment performed (denominator);  
f Cumulative proportion with severe PTS;   
g Composite of PTS or major non-PTS treatment failure. Villalta scores (0-33 range) – higher is worse; VCSS 




Table 4: Continuous Study Outcomes by Treatment Group (Intention To Treat) 
a Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and 
piece-wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race) 
b Model estimates are unchanged over visit times due to the lack of a significant time trend 
c Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and 
piece-wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race, Villalta score) 
d Mean change scores, SEs, and treatment differences estimated using multiple linear regression adjusted for 
center 
 (1) Villalta scores (0-33 range) – higher is worse;  
(2) VCSS scores (0-27 range) – higher is worse;  
(3) SF-36 major scales: physical component score (PCS, 0-100 range) and mental component score (MCS, 0-
100 range) – higher is better, with a difference of 3 to 4 points considered clinically meaningful;  
Outcome 
PCDT Arm 
n = 140 
Control Arm 
n = 160 
PCDT – Control 
Difference 
n mean (SE) n mean (SE) Estimate (SE) P-value 
Villalta mean scorea: (1)       
At 6 months 122 2.75 (0.52) 136 3.34 (0.51) -0.59 (0.44) 0.19 
At 12 months 117 2.86 (0.51) 121 3.35 (0.50) -0.50 (0.42) 0.24 
At 18 months 106 2.97 (0.52) 99 3.37 (0.52) -0.41 (0.45) 0.37 
At 24 months 113 3.08 (0.55) 107  3.39 (0.55) -0.32 (0.53) 0.55 
VCSS mean score bc : (2)       
At 6 months 121 1.87 (0.16) 134 2.12 (0.16) -0.26 (0.22) 0.25 
At 12 months 114 b 119 b b b 
At 18 months 105 b 94 b b b 
At 24 months 103 b 93  b b b 
SF-36 general Quality of Lifec: (3)       
PCS: Change, baseline to 24 months 107 12.00 (0.97) 99 11.03 (0.96) 0.97 (1.22) 0.43 
MCS: Change, baseline to 24 months 108 2.34 (0.67) 99 2.75 (0.67) -0.41 (0.87) 0.63 
VEINES disease-specific Quality of Lifec: (4)       
Overall: Change, baseline to 24 months 108 27.27 (2.04) 99 25.90 (2.01) 1.37 (2.54) 0.59 
Symptoms: Change, baseline to 24 months 108 20.60 (2.04) 99 20.14 (2.01) 0.46 (2.52) 0.86 
Leg pain severity§ (7-point scale): (5)       
Change, baseline to Day 10 136 -1.44 (0.15) 148 -1.35 (0.15) -0.09 (0.21) 0.68 
Change, baseline to Day 30 136 -1.93 (0.15) 146 -1.88 (0.15) -0.04 (0.22) 0.85 
Index leg circumferenced (cm): (6)       
Change, baseline to Day 10 130 0.45 (0.24) 146 0.37 (0.23) 0.08 (0.33) 0.81 
Change, baseline to Day 30 130 0.08 (0.25) 145 -0.41 (0.23) 0.50 (0.34) 0.14 
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(4) VEINES overall score (0-100 range) and symptom specific score (0-100 range) – higher is better;  
(5) patient-reported severity of pain in the index leg (0-7 range) – higher is worse;  






Fig. 1. Patient flow diagram for patients with femoral-popliteal DVT.
 
 
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep-vein thrombosis; LEP, 









Forest plot of risk ratios (PCDT vs. No PCDT) for the occurrence of PTS from 6 to 24 months 
among subgroups of patients. The horizontal lines represent 99% confidence intervals. 










Forest plot of risk ratios (PCDT vs. No PCDT) for the occurrence of moderate-or-severe PTS 
from 6 to 24 months among subgroups of patients. The horizontal lines represent 99% 
confidence intervals. 
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